Human Trials

Samsung Bioepis to start phase 1 trial of pancreatitis drug SB26

Samsung Bioepis said that it will soon start a phase 1 study to evaluate its pancreatitis drug SB26 in healthy volunteers.

Spark Therapeutics reports mixed results from hemophilia gene therapy trial

Spark Therapeutics’ SPK-8011, an investigational gene therapy treatment for hemophilia A, was successful in reducing bleeding in a phase 1/2 trial, but also resulted in one of the participants getting hospitalized.

Summit’s Ridinilazole preserves gut microbiome of patients with C. difficile infection

Summit Therapeutics said that its oral small molecule antibiotic ridinilazole was successful in preserving the gut microbiome of patients with C. difficile infection (CDI) during a phase 2 trial.

Arrowhead Pharmaceuticals secures $10m milestone payment from Amgen

Arrowhead Pharmaceuticals has secured a $10m milestone payment from Amgen, following the administration of the first dose of AMG 890, formerly referred to as ARO-LPA, in a clinical study.

Karuna raises $42m to advance KarXT into phase 2 study

Clinical-stage drug development firm Karuna Pharmaceuticals has completed $42m Series A financing round to advance selective muscarinic receptor agonist program into phase 2 study.

Celtaxsys’ CF drug acebilustat reduces pulmonary exacerbations in phase 2 trial

Celtaxsys' cystic fibrosis (CF) drug acebilustat has showed clinically meaningful improvements in pulmonary exacerbations in the phase 2 Empire-CF trial.

Investigator-initiated phase 2 trial to expand clinical evaluation of GKT831 into additional fibrotic disorder

Genkyotex said that US National Institutes of Health (NIH) has awarded an $8.9m grant to Professor Victor Thannickal at the University of Alabama at Birmingham (UAB) to fund a multi-year research program to assess the role of NOX enzymes in idiopathic pulmonary fibrosis (IPF).

Emergent starts phase 1 trial of Zika virus immune globulin therapeutic

Emergent BioSolutions has initiated a phase 1 clinical study to assess the safety and pharmacokinetics of its anti-Zika virus immune globulin ZIKV-IG, which is being developed as a therapeutic intervention against Zika virus disease.

RedHill’s RHB-104 meets primary endpoint in phase III Crohn’s disease study

RedHill Biopharma’s RHB-104 orally-administered antibiotic combination therapy has achieved its primary endpoint and key secondary endpoints in phase III Crohn’s disease study.